Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: 177Lu-octreotate PRRT is commonly administered at fixed/empiric activity per cycle, which results in highly variable radiation doses to critical organs and undertreatment of the majority of patients.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author:
Authors: Del Prete M, Buteau F, Beauregard J,
Keywords: personalized, PRRT, neuroendocrine tumors ,
Introduction: Everolimus is an oral inhibitor of mammalian target of rapamycin(mTOR) with antitumor activity in patients(pts) with pancreatic neuroendocrine tumor(pNET)s
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author: Del Prete M
Authors: Del Prete M, Malka L, Borget I, Berdelou A, Boige V,
Keywords: Pancreatic Neuroendocrine Tumor, Everolimus, Safety,
#904 Role of Metformin on Recurrence-Free Survival (RFS) in Neuroendocrine Tumors (NET)
Introduction: Recent data suggest metformin (Met) has antineoplastic properties in different type of cancer. Effects of Met have never been investigated in NET.
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author: Marciello F
Authors: Marciello F, Del Prete M, Marotta V, Ramundo V, Buonomano P,
Introduction: Somatostatin analogues (SSA) represent one of the main therapeutic options in patients affected by functioning well-differentiated neuroendocrine tumors (NETs). There are no studies specifically focusing on NETs associated with Multiple Endocrine Neoplasia type 1 (MEN1).
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author:
Authors: Ramundo V, Del Prete M, Marotta V, Marciello F, Camera L,
Keywords: somatostatin analogues, MEN1, neuroendocrine tumors, pancreatic neuroendocrine tumor,
Introduction: MTC is a well-differentiated neuroendocrine tumor in which somatostatin receptor (sst) expression is higher for sst1 and sst5 than for sst2. This may explain why the available sst2–selective analogues do not work in these patients and why pasireotide (SOM230), a novel, multi-receptor targeted somatostatin analogue with high-binding affinity for sst1, 2, 3 and sst5 could be effective.
Conference: 10th Annual ENETSConcerence (2013)
Presenting Author:
Authors: Faggiano A, Ferolla P, Vitale G, Del Prete M, Ramundo V,
Keywords: medullary thyroid cancer, pasireotide, somatostatin receptor,